Min-Han Tan

Min-Han Tan's Company

Min-Han Tan is the Founding CEO and Medical Director of a pioneering medical organization. Under his leadership, the company has made significant strides in the field of cancer research, particularly in the development of innovative multi-cancer screening tests. His visionary approach and dedication to advancing medical technology have positioned the company as a leader in the field of precision oncology and early cancer detection.

Min-Han Tan's Title

Min-Han Tan holds the dual titles of Founding CEO and Medical Director. These roles highlight his exceptional leadership and expertise in the medical field. As CEO, he oversees the strategic direction and operational management of the organization. As Medical Director, he ensures the highest standards of clinical practice and research are maintained, driving forward the company's mission to revolutionize cancer diagnostics and personalized care.

Min-Han Tan's Education and Expertise

Min-Han Tan holds both a PhD and an MBBS, reflecting his extensive medical and research training. His academic background has provided a strong foundation for his expertise in liquid biopsy technology, next-generation sequencing, and early cancer detection. His work on circulating tumor DNA (ctDNA) and cell-free RNA (cfRNA) has been instrumental in advancing personalized cancer care, making significant contributions to the field of oncology.

Min-Han Tan's Publications

Min-Han Tan has authored multiple publications in prestigious journals such as Annals of Oncology, Journal of Clinical Oncology, and American Association for Cancer Research. His research papers have been widely cited and have made substantial contributions to the understanding of cancer biology and the development of novel diagnostic technologies. These publications have solidified his reputation as a leading expert in oncology research.

Min-Han Tan's Achievements

Min-Han Tan has presented his groundbreaking research at major international conferences, including the ASCO Annual Meeting and the World Conference on Lung Cancer. His contributions to the development and evaluation of multi-cancer screening tests have been recognized globally. His collaborative studies on ctDNA and cfRNA have paved the way for advancements in early cancer detection and personalized medicine, earning him a distinguished place in the medical research community.